Table 1.

Characteristics of patients with CKD included in this analysis

VariablesAll (n=38,520)eGFR 45–59 (n=24,639)eGFR 30–44 (n=10,816)eGFR<30 (n=3695)
Age (years)72.8 (11.8)72.1 (11.3)74.5 (11.8)72.5 (14.1)
Male gender (n, %)16818 (43.7)10796 (43.8)4393 (43.1)1629 (44.1)
Blacks (n, %)5042 (13.1)2932 (11.9)1368 (13.4)742 (20.1)
Diabetes (n, %)8385 (21.8)5116 (20.8)2309 (22.7)960 (26.0)
Malignancy (n, %)9100 (23.6)6174 (25.1)2234 (21.9)692 (18.7)
Hypertension (n, %)31742 (82.4)20766 (84.3)8117 (79.7)2859 (77.4)
Hyperlipidemia (n, %)29038 (75.4)18974 (77.0)7437 (73.0)2627 (71.1)
Coronary artery disease (n, %)7479 (19.4)4642 (18.8)2091 (20.5)746 (20.2)
Congestive heart failure (n, %)2812 (7.3)1435 (5.8)964 (9.5)413 (11.2)
Body mass index (kg/m2)a29.3 (6.5)29.4 (6.4)29.3 (6.6)29.3 (6.9)
BMI group (n, %)
 <18.5 kg/m2460 (1.2)269 (1.1)136 (1.3)55 (1.5)
 18.5–24.9 kg/m28820 (22.9)5530 (22.4)2376 (23.3)914 (24.7)
 25–29.9 kg/m213099 (34.0)8578 (34.8)3392 (33.3)1129 (30.6)
 ≥30 kg/m213971 (36.3)9156 (37.2)3569 (35.0)1246 (33.7)
 Missing2170 (5.6)1106 (4.5)713 (7.0)351 (9.5)
Smoker (n, %)
 No28705 (74.5)19092 (77.5)7196 (70.6)2417 (65.4)
 Yes2586 (6.7)1680 (6.8)654 (6.4)252 (6.8)
 Missing7229 (18.8)3867 (15.7)2336 (22.9)1026 (27.8)
eGFR (ml/min per 1.73 m2)46.5 (11.1)53.4 (4.2)38.6 (4.2)22.2 (6.1)
Proteinuria (n, %)4861(26.5)2395(20.5)1438(30.1)1028(54.4)
Serum albumin (g/dl)a4.1 (0.5)4.1 (0.5)4.0 (0.5)3.9 (0.6)
Hemoglobin (g/dl)a12.8 (1.8)13.1 (1.7)12.5 (1.8)11.7 (1.8)
ACEI/ARB use (n, %)23620 (61.3)14715 (59.7)6553 (64.3)2352 (63.7)
Statins use (n, %)20984 (54.5)13536 (54.9)5481 (53.8)1967 (53.2)
Beta-blocker use (n, %)21198 (55.0)13084 (53.1)5866 (57.6)2248 (60.8)
Insurance (n, %)
 Medicare31364 (81.4)19851 (80.6)8542 (83.9)2971 (80.4)
 Medicaid258 (0.7)127 (0.5)82 (0.8)49 (1.3)
 Other5763 (15.0)3983 (16.2)1260 (12.4)520 (14.1)
 Missing1135 (2.9)678 (2.8)302 (3.0)155 (4.2)
  • a Missing data for each of the following: BMI n=2170, proteinuria n=20,173; serum albumin n=7294, hemoglobin n=6258.

  • ACEI/ARB, Angiotensin converting enzyme inhibitors/angiotensin receptor blockers.